Clinical Potential of GIP in Type 2 Diabetes and Obesity - PubMed
5 hours ago
- #Obesity Treatment
- #Type 2 Diabetes
- #GIP
- Incretin-based pharmacology has significantly advanced treatment for type 2 diabetes and obesity.
- Tirzepatide is a highly effective dual agonist targeting both GLP-1R and GIPR receptors.
- The success of tirzepatide has renewed interest in the clinical potential of GIPR agonism.
- GIPR activity may contribute to developing new effective drugs for metabolic disorders.
- Both GIPR agonists and antagonists are being explored for future therapeutic applications.